Bioclinica Acquires Saliency to Accelerate Digital Diagnostic Development
New AI integration dramatically speeds medical image interpretation and model creation within Bioclinica s imaging platform
News provided by
Share this article
Share this article
PRINCETON, N.J., Jan. 6, 2021 /PRNewswire/ Bioclinica, an integrated solutions provider of clinical life science and technology expertise, today announced that it has acquired Silicon Valley-based Saliency. Bioclinica will integrate the company s advanced AI technology into its Imaging Platform to support a growing portfolio of pharmaceutical and medical device clients. The integration will dramatically accelerate image QC and interpretation, enabling rapid development of digital diagnostics and digital therapeutics.
New Chief of the Division of Neonatology and Developmental Medicine Appointed by Stanford Children s Health
Lawrence (Lance) S. Prince, MD, PhD, will also serve as Co-director of the Johnson Center for Pregnancy and Newborn Services at Lucile Packard Children s Hospital Stanford, together with Co-director Yasser El-Sayed, MD, Obstetrician in Chief
News provided by
Share this article
Share this article
PALO ALTO, Calif., Jan. 6, 2021 /PRNewswire/ Physician-scientist and clinician Lawrence (Lance) S. Prince, MD, PhD, has been appointed Chief of the Division of Neonatal and Developmental Medicine at the Stanford University School of Medicine, as well as Professor of Pediatrics. He will also serve as Co-director of the Johnson Center for Pregnancy and Newborn Services at Lucile Packard Children s Hospital Stanford, together with Co-director Yasser El-Sayed, MD, Obstetrician in Chief.
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
Myeloid s cell therapy harnesses the innate capabilities of myeloid lineage cells to fight cancer
Scientific founders include world-renowned cell therapy & cancer experts Ronald Vale, Ph.D. and Siddhartha Mukherjee, M.D., D.Phil.
Co-Founded by Thomas Cahill, M.D., Ph.D., with financing led by Newpath Partners and participation from leading biotech investors
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ Myeloid Therapeutics, Inc., a company harnessing and reprogramming myeloid cells for treating cancers, launched today with over $50 million in financing to initiate multiple clinical trials in 2021. The Company combines advanced gene and cell engineering capabilities with substantial biologics knowledge to elucidate and redirect the power of myeloid cells to treat cancers, particularly solid tumors and those that are poorly served by exi
Most older adults with primary hyperparathyroidism (PHPT) did not receive definitive parathyroidectomy, researchers reported.
In a retrospective analysis of over 210,000 Medicare beneficiaries, only 30% underwent this operation within a year of their initial diagnosis, reported Carolyn Dacey Seib, MD, of Stanford University School of Medicine in California, and colleagues.
Out of the 131,723 of these patients with PHPT who met consensus guidelines criteria for undergoing this operative management defined as diagnosis of osteoporosis, nephrolithiasis, or stage 3 chronic kidney disease (CKD) only 29.6% underwent a parathyroidectomy, they stated in Parathyroidectomy is the only definitive treatment for PHPT, Seib s group wrote, adding that Evidence based criteria for the operative management of PHPT have expanded significantly since the first consensus guidelines were published in 1991.
Consider for a moment, in this time of anguish and loss and death, of mass unemployment and flattened national economies, the Twilight Zone alternate reali